VONZARGO Trademark

Trademark Overview

On Wednesday, March 10, 2021, a trademark application was filed for VONZARGO with the United States Patent and Trademark Office. The USPTO has given the VONZARGO trademark a serial number of 90569849. The federal status of this trademark filing is WITHDRAWN BEFORE PUBLICATION as of Thursday, June 6, 2024. This trademark is owned by TAIHO PHARMACEUTICAL CO., LTD.. The VONZARGO trademark is filed in the Pharmaceutical Products category with the following description:

Anti-cancer preparations; pharmaceutical preparations for the treatment of tumor; chemical reagents for medical purposes in the field of oncology
vonzargo

General Information

Serial Number90569849
Word MarkVONZARGO
Filing DateWednesday, March 10, 2021
Status692 - WITHDRAWN BEFORE PUBLICATION
Status DateThursday, June 6, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesAnti-cancer preparations; pharmaceutical preparations for the treatment of tumor; chemical reagents for medical purposes in the field of oncology

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, June 9, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTAIHO PHARMACEUTICAL CO., LTD.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTokyo 101-8444
JP
Party NameTAIHO PHARMACEUTICAL CO., LTD.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTokyo 101-8444
JP

Trademark Events

Event DateEvent Description
Wednesday, June 9, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, March 13, 2021NEW APPLICATION ENTERED
Monday, October 4, 2021ASSIGNED TO EXAMINER
Wednesday, October 13, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 27, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 16, 2021PUBLISHED FOR OPPOSITION
Tuesday, November 16, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 11, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, July 1, 2022SOU TEAS EXTENSION RECEIVED
Friday, July 1, 2022SOU EXTENSION 1 FILED
Friday, July 1, 2022SOU EXTENSION 1 GRANTED
Tuesday, July 5, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 9, 2022SOU TEAS EXTENSION RECEIVED
Friday, December 9, 2022SOU EXTENSION 2 FILED
Friday, December 9, 2022SOU EXTENSION 2 GRANTED
Tuesday, December 13, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 12, 2023SOU TEAS EXTENSION RECEIVED
Monday, June 12, 2023SOU EXTENSION 3 FILED
Monday, June 12, 2023SOU EXTENSION 3 GRANTED
Wednesday, June 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 1, 2023SOU TEAS EXTENSION RECEIVED
Friday, December 1, 2023SOU EXTENSION 4 FILED
Friday, December 1, 2023SOU EXTENSION 4 GRANTED
Tuesday, December 5, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 19, 2024SOU TEAS EXTENSION RECEIVED
Friday, April 19, 2024SOU EXTENSION 5 FILED
Friday, April 19, 2024SOU EXTENSION 5 GRANTED
Saturday, April 20, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 25, 2024TEAS PETITION TO AMEND BASIS RECEIVED
Monday, June 3, 2024PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Monday, June 3, 2024ASSIGNED TO PETITION STAFF
Tuesday, June 4, 2024NOTICE OF ALLOWANCE CANCELLED
Thursday, June 6, 2024ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Tuesday, June 4, 2024CASE RETURNED TO EXAMINATION

Related Keywords

vonzargo preparations medical purposes field reagents oncology tumor cancer pharmaceutical treatment